Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model Wim MaesStefaan W. Van Gool Review 01 December 2010 Pages: 153 - 160
Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 Jürgen KuballKarin de BoerMatthias Theobald Original Article Open access 21 October 2010 Pages: 161 - 171
Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy Matthias WölflKatharina MerkerPaul G. Schlegel Original Article 24 October 2010 Pages: 173 - 186
Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis Richard J. WarringtonKeith E. Lewis Original Article 26 October 2010 Pages: 187 - 195
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination Matteo VergatiVittore CeredaKwong Y. Tsang Original Article 26 October 2010 Pages: 197 - 206
Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer Motoyoshi KurosakiShigetoshi HoriguchiYoshitaka Okamoto Original Article 27 October 2010 Pages: 207 - 215
Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence Salomé González-ReyesJesús M. FernándezFrancisco J. Vizoso Original Article 27 October 2010 Pages: 217 - 226
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors Rikke Sick AndersenRikke Bæk SørensenMads Hald Andersen Original Article Open access 28 October 2010 Pages: 227 - 234
IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype Jana AlbrechtMichaela FreyEva Distler Original Article 03 November 2010 Pages: 235 - 248
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used W. Joost LesterhuisGerty SchreibeltCornelis J. A. Punt Original Article 11 November 2010 Pages: 249 - 260
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings Stéphane OudardOlivier RixeEric Tartour Original Article 11 November 2010 Pages: 261 - 271
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery Gregory DriessensLise NuttinCatherine Bruyns Original Article 13 November 2010 Pages: 273 - 281
CDR2 antigen and Yo antibodies Cecilie TotlandNina K. AarskogChristian A. Vedeler Original Article Open access 16 November 2010 Pages: 283 - 289
CD8 Co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression Andrew ZlozaMichael C. JagodaJosé A. Guevara-Patiño Short Communication 31 December 2010 Pages: 291 - 297
“Tumor immunology meets oncology (TIMO) VI” from 7th to 8th of May 2010 in Halle, Germany Dagmar QuandtChiara MassaBarbara Seliger Meeting Report 28 August 2010 Pages: 299 - 303